Means for inhibiting the expression of orc-1
AssigneeSilence Therapeutics GmbH
InventorsManfred Gossen, Ansgar Santel, Jorg Kaufmann
Life of this patent
Estimating the term…
Loading patent…
AssigneeSilence Therapeutics GmbH
InventorsManfred Gossen, Ansgar Santel, Jorg Kaufmann
Estimating the term…
The present invention is related to a nucleic acid molecule comprising a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic acid, and whereby the second strand comprises a second stretch of contiguous nucleotides and said second stretch is at least partially complementary to the first stretch, whereby the first stretch comprises a nucleic acid sequence which is at least complementary to a nucleotide core sequence of the nucleic acid sequence according to SEQ ID NO: 1, whereby the nucleotide core sequence comprises the nucleotide sequence from nucleotide positions 1755 to 1763 of SEQ ID NO: 1; from nucleotide positions 1904 to 1912 of SEQ. ID. No.1; from nucleotide positions 1905 to 1913 of SEQ ID NO: 1; from nucleotide positions 2548 to 2556 of SEQ ID NO: 1; whereby the first stretch is additionally at least partially complementary to a region preceding the 5′ end of the nucleotide core sequence and/or to a region following the 3′ end of the nucleotide core sequence.
1-34. (canceled)
A nucleic acid molecule comprising a double-stranded structure that is optionally covalently linked,
Dependencies are inferred from the claim text.